Skip to main content
. 2022 Sep 14;10(9):e005136. doi: 10.1136/jitc-2022-005136

Table 1.

Clinicopathological variables of study population

Discovery set (N=16) Validation set
(N=15)
Sex
 Female 5 (31%) 4 (27%)
 Male 11 (69%) 11 (73%)
Age
 ≥66 9 (56%) 7 (47%)
 <66 7 (44%) 8 (53%)
Therapy line
 Second 13 (81%) 12 (75%)
 Third 3 (19%) 3 (25%)
First-line TKI
 Sunitinib 11 (69%) 8 (53%)
 Pazopanib 5 (31%) 7 (47%)
IMDC score
 Good risk 5 (31%) 5 (33%)
 Intermediate risk 11 (69%) 10 (67%)

IMDC, International Metastatic RCC Database Consortium; TKI, tyrosine kinase inhibitor.